Capable Platform Yposkesi operates one of Europe’s largest CDMOs for gene therapy viral vectors, with LV and AAV cGMP manufacturing and plans to scale capacity significantly, signaling a strong opportunity to secure sustained manufacturing partnerships for late-stage programs.

Expansion Readiness Upcoming expansion to double facility space and obtain EMA and FDA-compliant operations suggests a readiness to onboard additional clients and programs, making it a favorable target for collaboration on scale-up, tech transfer, and regulatory-ready manufacturing.

Pipeline Innovation Recent launches of LentiSure, LentiSure platform for LV production and AAVelocity for AAV platforms indicate a diversified, platform-first approach that can attract companies seeking versatile viral vector manufacturing capabilities and plug-and-play solutions.

Strategic Location Located near Paris with access to European regulatory ecosystems and a growing biopharma hub, Yposkesi offers geographic and regulatory advantages for European clinical trials and commercialization timelines.

Leadership and Credentials Recent executive appointments and SK pharmteco backing imply strong corporate support, quality assurance, and strategic alignment, which can reassure prospective customers about reliability, quality systems, and long-term partnerships.